Granules India Ltd and its subsidiaries, specializing in Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages, posted impressive financial results for Q2FY26.
Financial Highlights:
- Revenues increased 34.13% year-on-year to ₹1,297 crore from ₹967 crore.
- Total expenses rose 33.02% to ₹1,120 crore from ₹842 crore.
- Consolidated net profit jumped 35.05% to ₹131 crore from ₹97 crore.
- Earnings per share improved 34.16% to ₹5.38 from ₹4.01.
The strong operational performance was driven by rising export demand, product diversification, and improved cost management.
Outlook:
Granules India is focused on expanding global market share, launching complex generics, and strengthening its manufacturing capabilities. Continued investment in research and development will support innovation and sustain future growth.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.
Most Popular
Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
All you need to know about Antony Waste Handling Cell in one article
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
Demystifying the Leading Non-Ferrous Recycling Company of India
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,